Human PD-L1 inhibitor II|CAS 2135542-85-5|DC Chemicals

Cas No.:	2135542-85-5
Chemical Name:	Human PD-L1 inhibitor II
Synonyms:	FNWDYSLEELREKAKYK
Formula:	C₁₀₃H₁₅₁N₂₅O₃₀
M.Wt:	2219.45
Sotrage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Cat. No.	Product name	Field of application
DC46565	PD-1-IN-20	PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.
DC46218	PD-1-IN-17 TFA	PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
DC44156	TPP-1 TFA	TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function.
DC44155	TPP-1	TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.
DC42066	Human PD-L1 inhibitor III	Human PD-L1 inhibitor III is a human PD-L1 inhibitor.
DC41989	Human PD-L1 inhibitor V	Human PD-L1 inhibitor V, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1.
DC41988	Human PD-L1 inhibitor IV	Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1.
DC41982	Human PD-L1 inhibitor II	Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.
DC28554	PD-1/PD-L1-IN 5	PD-1/PD-L1-IN 5 is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM.
DC28140	PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1-IN 3 TFA is a PD-1/PD-L1 interaction inhibitor extracted from patent WO2014151634A1, compound 1. PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM.